US Patent

US10245276 — Co-crystals of tramadol and coxibs

Composition of Matter · Assigned to Laboratorios del Dr Esteve SA · Expires 2030-04-19 · 4y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects co-crystals of tramadol and coxibs, including their preparation and use as medicaments for treating pain.

USPTO Abstract

The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.

Drugs covered by this patent

Celebrex (celecoxib) · Pfizer Inc. (originally Searle/Pharmacia)

Patent Metadata

Patent number: US10245276
Jurisdiction: US
Classification: Composition of Matter
Expires: 2030-04-19
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Laboratorios del Dr Esteve SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.